Mineralys Therapeutics
Trade Mineralys Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
MLYS Key Statistics
Stock Snapshot
The current Mineralys Therapeutics(MLYS) stock price is $27.04, with a market capitalization of 2.41B. The stock trades at a price-to-earnings (P/E) ratio of -13.25.
On 2026-07-15, Mineralys Therapeutics(MLYS) stock traded between a low of $26.39 and a high of $27.33. Shares are currently priced at $27.04, which is +2.5% above the low and -1.1% below the high.
Mineralys Therapeutics(MLYS) shares are trading with a volume of 501.23K, against a daily average of 1.14M.
In the last year, Mineralys Therapeutics(MLYS) shares hit a 52-week high of $47.65 and a 52-week low of $12.59.
In the last year, Mineralys Therapeutics(MLYS) shares hit a 52-week high of $47.65 and a 52-week low of $12.59.
Analyst ratings
89%
of 9 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.